During cold and flu season, it can be challenging to differentiate illnesses like the common cold, flu, COVID-19, respiratory syncytial virus (RSV), and norovirus. Each show distinct symptoms, modes ...
For a second year in a row, Currax delivered greater than 50% year-over-year revenue growth for CONTRAVE®/MYSIMBA® in 2024. These outsized results were driven by increased patient demand, improved ...